Catalyst Capital, the European real estate investment and asset management firm, has completed the first letting at Kings House, Hammersmith, following its £50m purchase on behalf of a private investor of the 60,000 sq ft seven-floor office building at the end of 2019.
Alvogen is a global, privately-owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. This will be Alvogen’s first UK office base as it continues to grow.
Alvogen has taken 5,500 sq ft on a 5-year lease term, leaving just the 6,500 sq ft part first floor available before full occupancy is achieved at Kings House.
Kings House is a new, high-quality, self-contained, sustainable office building split over seven floors, totalling 60,000 sq ft, in the heart of Hammersmith.
Alvogen joins a range of occupiers including HyperOptic, Work.Life, 4C Associates, Zaizi and SailGB.
Catalyst Capital is advised by Frost Meadowcroft and Lambert Smith Hampton (LSH).
Justin Clack, director at Frost Meadowcroft added:
“We think that the COVID 19 crisis will mean that the tenants are more likely to lease the ‘best in class’ offices available in individual submarkets, such as Kings House in Hammersmith”.
Sarah Cooper, Portfolio Manager for Catalyst Capital, added:
“We are delighted to welcome Alvogen to Kings House. Its offices have been fitted to a high specification, which in turn reflects the quality of the building in a prime location within Hammersmith”.
